(Xconomy) Trubion Pharmaceuticals a one-time highflier in Seattle’s biotech community, said today it is getting acquired for less than $100 million upfront. The buyer is Rockville, MD-based Emergent Biosolutions (NYSE: EBS). Shareholders in Trubion (NASDAQ: TRBN) will get a total of $96.8 million in an upfront payment from Emergent, plus as much as $38.7 million in success-based